CN Patent

CN113024516B — 双靶点parp/ezh2抑制剂、制备方法及用途

Assigned to China Pharmaceutical University · Expires 2022-05-17 · 4y expired

What this patent protects

本发明公开了如通式(I)和(II)所示结构的双靶点PARP/EZH2抑制剂或其可药用的盐，本发明的抑制剂对人乳腺癌细胞MDA‑MB‑231和MDA‑MB‑468和MCF‑7抑制效果较好，对人正常乳腺细胞MCF‑10A和人正常肝细胞L02毒性较小，并且保持了良好的对PARP‑1和EZH2的体外抑制活性，有作为抗肿瘤药物的巨大潜力。

USPTO Abstract

本发明公开了如通式(I)和(II)所示结构的双靶点PARP/EZH2抑制剂或其可药用的盐，本发明的抑制剂对人乳腺癌细胞MDA‑MB‑231和MDA‑MB‑468和MCF‑7抑制效果较好，对人正常乳腺细胞MCF‑10A和人正常肝细胞L02毒性较小，并且保持了良好的对PARP‑1和EZH2的体外抑制活性，有作为抗肿瘤药物的巨大潜力。

Drugs covered by this patent

Patent Metadata

Patent number: CN113024516B
Jurisdiction: CN
Classification: —
Expires: 2022-05-17
Drug substance claim: No
Drug product claim: No
Assignee: China Pharmaceutical University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.